The Global Innovation Award has a top prize of $1 million.
The Hebrew University tech transfer company will collaborate on a novel delivery system.
Know what keeps Ruth Gallily up at night? The Hebrew University immunology professor emerita is frustrated to know how many people could benefit from medical cannabis if only more countries would make it available in pharmacies.
Blue-and-white technology converts toxic hydrocarbons into benign material, without further harm to flora and fauna.
The technology, which was patented and commercialized by Hebrew University’s technology transfer company Yissum, was sold to the Swiss firm Man Oil Group about a year ago.
The New Technology invented by Prof. Yoel Sasson and Dr. Uri Stoin was licensed to Swiss Co. Man Oil Group.
EyeMusic- A New Tachnology by Prof. Amir Amedi gives a new meaning to sound and vision for the blind.
Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, has received a $3 million investment from China's Guangxi Wuzhou Pharmaceutical Group. The funds raised will be used to advance Integra Holdings’ existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.
The BreedIT system is based in part by research conducted by Professors Haim Rabinowitch and Nachum Kedar of Hebrew University, most famous for their work in developing popular strains of cherry tomatoes and perfecting long-life tomatoes that contain a ripening inhibitor gene to guarantee a longer shelf life.
The new technology, according to BreedIT CEO Dr. Oded Sagee, is essential to the development of the medical marijuana industry – which Sagee believes is set for a major worldwide expansion. “We decided to develop an organized breeding program to assist breeders to develop new breeds of cannabis,”
Israeli Tech Transfer Offices are world leaders in their ability to turn ealy-stage inventions to products on market. [Hebrew article).
Lockheed Martin Israel Ltd. and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, have signed an agreement to conduct joint collaborative research. The collaboration will focus on basic and applicable scientific research in areas such as quantum information sciences and material sciences, and other areas.
A top US health agency is working with an Israeli start-up to develop solutions to ‘flesh-eating’ septic bio-threats
We are happy to share with you some of the exciting events of our Year of Jubilee.
Hyrax licenses the technology for YIssum to produce new printers that will use silver-based inks for to revolutionize conductive printing.
The first gateway for Korean companies to the world of Israeli Academic Innovation.
The many groundbreaking products that came out of the labs of the Hebrew University of Jerusalem (HUJI) – including the blockbuster drugs Exelon and Doxil, as well as the hardy cherry tomato – may never have moved from academia to market without Yissum Research Development Company, founded in February 1964 to protect and commercialize HUJI’s intellectual property.
Jerusalem-based Mobileye’s IPO surpassed Partner Communication Ltd’s share sale of $525 million in October 1999 to become the biggest U.S. IPO by an Israeli company. Founded by Hebrew University professor Amnon Shashua and Ziv Aviram 15 years ago, Mobileye makes a chip and a system that alert drivers to pedestrians and unintended lane departures. The company’s products will help enable hands-free driving on the highway by 2016, according to the filing.
The funds will enable Atox Bio to initiate a late stage clinical study of AB103, for the treatment of necrotising soft tissue infections (NSTI), commonly referred to as the "flesh eating bacteria" and other severe infections. The study is expected to start in the second half of 2015.
AB103, an immunomodulator licensed from Yissum, the technology transfer company of the Hebrew University In Jerusalem, is a peptide that offers a unique approach in the treatment of infectious diseases by modulating, but not inhibiting, the host immune system.
Known as the Startup Nation, Israeli startups have now taken their expertise in innovation and technology to create revolutionary tools for the blind and visually impaired, two of them from Hebrew university researchers.
The next interim results expected at Q3 2015, following 2 years of treatment; final results expected at Q3 2016, following 3 years of treatment